Synthetic CXCR4 Antagonistic Peptide Assembling with Nanoscaled Micelles Combat Acute Myeloid Leukemia

AML: New Drugs but New Challenges

(2020) Alan Burnett et al.   Clinical Lymphoma Myeloma & Leukemia

PIM1 inhibition effectively enhances plerixafor-induced HSC mobilization by counteracting CXCR4 upregulation and blocking CXCL12 secretion

(2019) Tony Andreas Müller et al.   LEUKEMIA

Modulators of CXCR4 and CXCR7/ACKR3 function

(2019) Ilze Adlere et al.   MOLECULAR PHARMACOLOGY

A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia

(2018) David Martínez-Cuadrón et al.   ANNALS OF HEMATOLOGY

CXCR4-mediated signaling regulates autophagy and influences acute myeloid leukemia cell survival and drug resistance

(2018) Xiaojia Hu et al.   CANCER LETTERS

Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell

(2018) Jonathan Hoggatt et al.   CELL

Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma

(2018) Eudocia Q Lee et al.   CLINICAL CANCER RESEARCH

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia

(2018) Gail J Roboz et al.   HAEMATOLOGICA

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia

(2018) Gail J Roboz et al.   HAEMATOLOGICA

Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21)

(2018) Ya-Zhen Qin et al.   Blood Cancer Journal

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

(2018) Prajwal Boddu et al.   Frontiers in Oncology

Functional genomic landscape of acute myeloid leukaemia

(2018) Jeffrey W. Tyner et al.   NATURE

D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia

(2017) Ikuko Omori et al.   EXPERIMENTAL HEMATOLOGY

Relevance of Half-Life in Drug Design

(2017) Dennis A. Smith et al.   JOURNAL OF MEDICINAL CHEMISTRY

Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial

(2017) Darja Karpova et al.   Journal of Translational Medicine

The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression

(2017) M Abraham et al.   LEUKEMIA

A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive‐disease small cell lung cancer

(2017) Ravi Salgia et al.   LUNG CANCER

A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Co

(2017) Todd M. Cooper et al.   PEDIATRIC BLOOD & CANCER

Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587

(2017) Sheng-Bin Peng et al.   Oncotarget

Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia

(2016) Breanne Landry et al.   JOURNAL OF CONTROLLED RELEASE

A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)

(2016) John D. Hainsworth et al.   Targeted Oncology

‘Acute myeloid leukemia: a comprehensive review and 2016 update’

(2016) I De Kouchkovsky et al.   Blood Cancer Journal

Dynamic Biostability, Biodistribution, and Toxicity of l/d-Peptide-Based Supramolecular Nanofibers

(2015) Cuihong Yang et al.   ACS Applied Materials & Interfaces

Acute myeloid leukemia-Major progress over four decades and glimpses into the future

(2015) Hagop Kantarjian   AMERICAN JOURNAL OF HEMATOLOGY

Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy

(2015) B.-S. Cho et al.   BLOOD

Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment

(2015) S. Scala   CLINICAL CANCER RESEARCH

CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks

(2015) F Guo et al.   ONCOGENE

A novel SAHA-bendamustine hybrid induces apoptosis of leukemia cells

(2015) Jing Yu et al.   Oncotarget

Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis

(2015) Xiaojin Li et al.   Scientific Reports

Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models

(2014) S.-B. Peng et al.   MOLECULAR CANCER THERAPEUTICS

Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo

(2014) K. Beider et al.   MOLECULAR CANCER THERAPEUTICS

A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo

(2014) Xiaojin Li et al.   Scientific Reports

HPMA Copolymer CXCR4 Antagonist Conjugates Substantially Inhibited the Migration of Prostate Cancer Cells

(2014) Zheng-Hong Peng et al.   ACS Macro Letters

Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140

(2013) K. Beider et al.   CLINICAL CANCER RESEARCH

The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma

(2013) A. Peled et al.   CLINICAL CANCER RESEARCH

Role of CXCR4 in the Pathogenesis of Acute Myeloid Leukemia

(2013) Amnon Peled et al.   Theranostics

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

(2012) G. L. Uy et al.   BLOOD

In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non–small cell lung cancer

(2012) Duha Fahham et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice

(2011) L. Zhao et al.   BLOOD

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome

(2011) D. C. Dale et al.   BLOOD

The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation

(2011) M Mohty et al.   LEUKEMIA

Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia

(2011) S Wakita et al.   LEUKEMIA

C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice

(2011) Y.-Y. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Update on clinical experience with AMD3100, an SDF-1/CXCL12–CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells

(2010) Iskra Pusic et al.   CURRENT OPINION IN HEMATOLOGY

CXCR4 chemokine receptor antagonists: perspectives in SCLC

(2009) Jan A Burger et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Specific Interactions between the Viral Coreceptor CXCR4 and the Biguanide-Based Compound NB325 Mediate Inhibition of Human Immunodeficiency Virus Type 1 Infection

(2008) N. Thakkar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction

(2008) S. M. Devine et al.   BLOOD

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100

(2008) B. Nervi et al.   BLOOD

The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation

(2008) S Tavor et al.   LEUKEMIA

CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers

(2008) J A Burger et al.   LEUKEMIA